These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 27127129)

  • 1. PIK3CA Mutations Detected in Patients with Central Nervous System Metastases of Non-small Cell Lung Cancer.
    Nicoś M; Krawczyk P; Powrózek T; Szudy P; Jarosz B; Sawicki M; Szumiło J; Trojanowski T; Milanowski J
    Anticancer Res; 2016 May; 36(5):2243-9. PubMed ID: 27127129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitive methods for screening of the MEK1 gene mutations in patients with central nervous system metastases of non-small cell lung cancer.
    Nicoś M; Krawczyk P; Jarosz B; Sawicki M; Michnar M; Trojanowski T; Milanowski J
    Clin Transl Oncol; 2016 Oct; 18(10):1039-43. PubMed ID: 26860843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases.
    Allison DB; Lilo MT; Geddes S; Pallavajjalla A; Askin F; Gabrielson E; Zheng G; Li QK
    Cancer Cytopathol; 2016 Jul; 124(7):485-92. PubMed ID: 27007084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
    Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
    J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic mutation screen in early non--small-cell lung cancer (NSCLC) specimens.
    Bar J; Damianovich M; Hout Siloni G; Dar E; Cohen Y; Perelman M; Ben Nun A; Simansky D; Yellin A; Urban D; Onn A
    Clin Lung Cancer; 2014 Mar; 15(2):159-65. PubMed ID: 24370118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies.
    Scheffler M; Bos M; Gardizi M; König K; Michels S; Fassunke J; Heydt C; Künstlinger H; Ihle M; Ueckeroth F; Albus K; Serke M; Gerigk U; Schulte W; Töpelt K; Nogova L; Zander T; Engel-Riedel W; Stoelben E; Ko YD; Randerath W; Kaminsky B; Panse J; Becker C; Hellmich M; Merkelbach-Bruse S; Heukamp LC; Büttner R; Wolf J
    Oncotarget; 2015 Jan; 6(2):1315-26. PubMed ID: 25473901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The presence of HER2 exon 20 insertion in patients with central nervous system metastases from non-small lung cancer--a potential application in classification for therapy.
    Nicoś M; Krawczyk P; Mlak R; Sawicki M; Jarosz B; Powrózek T; Milanowski P; Trojanowski T; Milanowski J
    Pneumonol Alergol Pol; 2013; 81(4):294-7. PubMed ID: 23744164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology.
    Ludovini V; Pistola L; Gregorc V; Floriani I; Rulli E; Piattoni S; Di Carlo L; Semeraro A; Darwish S; Tofanetti FR; Stocchi L; Mihaylova Z; Bellezza G; Del Sordo R; Daddi G; Crinò L; Tonato M
    J Thorac Oncol; 2008 Apr; 3(4):365-73. PubMed ID: 18379354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR activating mutations detected by different PCR techniques in Caucasian NSCLC patients with CNS metastases: short report.
    Kamila WK; Michał S; Paweł K; Paulina J; Tomasz K; Bożena J; Radosław M; Justyna S; Marek S; Trojanowski T; Janusz M; Joanna CW
    Clin Exp Metastasis; 2013 Dec; 30(8):1063-71. PubMed ID: 23892415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer.
    Daniele L; Cassoni P; Bacillo E; Cappia S; Righi L; Volante M; Tondat F; Inghirami G; Sapino A; Scagliotti GV; Papotti M; Novello S
    J Thorac Oncol; 2009 Jun; 4(6):684-8. PubMed ID: 19404216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PIK3CA mutation status in Japanese lung cancer patients.
    Kawano O; Sasaki H; Endo K; Suzuki E; Haneda H; Yukiue H; Kobayashi Y; Yano M; Fujii Y
    Lung Cancer; 2006 Nov; 54(2):209-15. PubMed ID: 16930767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 gene mutations in non-small cell lung cancer detected by polymerase chain reaction single-strand conformation polymorphism analysis.
    Zhao Y; Wu D; Xiang X; Zhang B; Zhou N; Hu Y
    Chin Med Sci J; 1999 Sep; 14(3):134-7. PubMed ID: 12903811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early stage non-small cell lung cancer patients need brain imaging regardless of symptoms.
    Ando T; Kage H; Saito M; Amano Y; Goto Y; Nakajima J; Nagase T
    Int J Clin Oncol; 2018 Aug; 23(4):641-646. PubMed ID: 29484515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of NRAS, PTEN and AKT1 gene mutations in the central nervous system metastases of non-small cell lung cancer.
    Nicoś M; Krawczyk P; Jarosz B; Sawicki M; Trojanowski T; Milanowski J
    Brain Tumor Pathol; 2017 Jan; 34(1):36-41. PubMed ID: 28097440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The expression of three genes in primary non-small cell lung cancer is associated with metastatic spread to the brain.
    Grinberg-Rashi H; Ofek E; Perelman M; Skarda J; Yaron P; Hajdúch M; Jacob-Hirsch J; Amariglio N; Krupsky M; Simansky DA; Ram Z; Pfeffer R; Galernter I; Steinberg DM; Ben-Dov I; Rechavi G; Izraeli S
    Clin Cancer Res; 2009 Mar; 15(5):1755-61. PubMed ID: 19190132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PIK3CA mutations in head and neck squamous cell carcinoma.
    Qiu W; Schönleben F; Li X; Ho DJ; Close LG; Manolidis S; Bennett BP; Su GH
    Clin Cancer Res; 2006 Mar; 12(5):1441-6. PubMed ID: 16533766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene mutations in squamous cell NSCLC: insignificance of EGFR, KRAS and PIK3CA mutations in prediction of EGFR-TKI treatment efficacy.
    Fiala O; Pesek M; Finek J; Benesova L; Bortlicek Z; Minarik M
    Anticancer Res; 2013 Apr; 33(4):1705-11. PubMed ID: 23564819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of PIK3CA gene mutations with HRM analysis and association with IGFBP-5 expression levels in breast cancer.
    Dirican E; Kaya Z; Gullu G; Peker I; Ozmen T; Gulluoglu BM; Kaya H; Ozer A; Akkiprik M
    Asian Pac J Cancer Prev; 2014; 15(21):9327-33. PubMed ID: 25422220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer.
    He C; Liu M; Zhou C; Zhang J; Ouyang M; Zhong N; Xu J
    Int J Cancer; 2009 Nov; 125(10):2393-9. PubMed ID: 19530244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases.
    Han HS; Eom DW; Kim JH; Kim KH; Shin HM; An JY; Lee KM; Choe KH; Lee KH; Kim ST; Koo JH; Lee HC; Lee OJ
    Clin Lung Cancer; 2011 Nov; 12(6):380-6. PubMed ID: 21729655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.